Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Purpose: Gonadotropin-releasing hormone (GnRH) agonists decrease bone mineral density, a surrogate for fracture risk, in men with prostate cancer. We conducted a claims-based cohort study to characterize the relationship between GnRH agonists and risk for clinical fractures in men with nonmetastatic prostate cancer. Patients and Methods: Using medical claims data from a 5% national random sample of Medicare beneficiaries, we identified a study group of men with nonmetastatic prostate cancer who initiated GnRH agonist treatment from 1992 to 1994 (n = 3,887). A comparison group of men with nonmetastatic prostate cancer who did not receive GnRH agonist treatment during the study period (n = 7,774) was matched for age, race, geographic location, and comorbidity. Clinical fractures were identified using inpatient, outpatient, and physician claims during 7 years of follow-up. Results: In men with nonmetastatic prostate cancer, GnRH agonists significantly increased fracture risk. The rate of any clinical fracture was 7.88 per 100 person-years at risk in men receiving a GnRH agonist compared with 6.51 per 100 person-years in matched controls (relative risk, 1.21; 95% CI, 1.14 to 1.29; P < .001). Rates of vertebral fractures (relative risk, 1.45; 95% CI, 1.19 to 1.75; P < .001) and hip/femur fractures (relative risk, 1.30; 95% CI, 1.10 to 1.53; P = .002) were also significantly higher in men who received a GnRH agonist. GnRH agonist treatment independently predicted fracture risk in multivariate analyses. Longer duration of treatment conferred greater fracture risk. Conclusion: GnRH agonists significantly increase risk for any clinical fracture, hip fractures, and vertebral fractures in men with prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y.-F., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375
Use of Inhaled Corticosteroids and Risk of Fractures
Van Staa, T. P., Leufkens, H. G. M., & Cooper, C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.581 · Cited by 1,308
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
The crippling consequences of fractures and their impact on quality of life
Cooper, C. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)90022-x · Cited by 699
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A., Kantoff, P. W., & Finkelstein, J. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010845 · Cited by 696
Self-citation(1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.d01-6840.x · Cited by 654
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Self-citationMohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Self-citationAdverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
Self-citationGalvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2488 · Cited by 657
Bone health in cancer patients: ESMO Clinical Practice Guidelines
Coleman, R., Body, J. J., Aapro, M., Hadji, P., & Herrstedt, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu103 · Cited by 564
Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases
Guise, T. A., Mohammad, K. S., Clines, G., Stebbins, E. G., Wong, D. H., Higgins, L. S., Vessella, R., Corey, E., Padalecki, S., Suva, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1007 · Cited by 539
Denham, J. W., Steigler, A., Lamb, D. S., Joseph, D., Turner, S., Matthews, J., Atkinson, C., North, J., Christie, D., Spry, N. A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70063-8 · Cited by 450
Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone
Kobayashi, A., Okuda, H., Xing, F., Pandey, P. R., Watabe, M., Hirota, S., Pai, S. K., Liu, W., Fukuda, K., Chambers, C., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110840 · Cited by 427
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Snyder, P. J., Kopperdahl, D. L., Stephens-Shields, A. J., Ellenberg, S. S., Cauley, J. A., Ensrud, K. E., Lewis, C. E., Barrett-Connor, E., Schwartz, A. V., Lee, D. C., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9539 · Cited by 363
Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes
Alibhai, S. M. H., Duong-Hua, M., Sutradhar, R., Fleshner, N. E., Warde, P., Cheung, A. M., & Paszat, L. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0923 · Cited by 334
MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management
Mirza, F., & Canalis, E. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0118 · Cited by 331
Michaelson, M. D., Kaufman, D. S., Lee, H., McGovern, F. J., Kantoff, P. W., Fallon, M. A., Finkelstein, J. S., & Smith, M. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3361 · Cited by 330
Self-citationReview of major adverse effects of androgen‐deprivation therapy in men with prostate cancer
Taylor, L. G., Canfield, S. E., & Du, X. L. (2009) · Cancer · doi:10.1002/cncr.24283 · Cited by 324
Resistance Training and Reduction of Treatment Side Effects in Prostate Cancer Patients
GALVÃO, D. A., NOSAKA, K., TAAFFE, D. R., SPRY, N., KRISTJANSON, L. J., MCGUIGAN, M. R., SUZUKI, K., YAMAYA, K., & NEWTON, R. U. (2006) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000233803.48691.8b · Cited by 297
Castration-Resistant Prostate Cancer: AUA Guideline
Cookson, M. S., Roth, B. J., Dahm, P., Engstrom, C., Freedland, S. J., Hussain, M., Lin, D. W., Lowrance, W. T., Murad, M. H., Oh, W. K., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.05.005 · Cited by 275
Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer
Galvão, D. A., Spry, N. A., Taaffe, D. R., Newton, R. U., Stanley, J., Shannon, T., Rowling, C., & Prince, R. (2008) · BJU International · doi:10.1111/j.1464-410x.2008.07539.x · Cited by 270
Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer
Pagliarulo, V., Bracarda, S., Eisenberger, M. A., Mottet, N., Schröder, F. H., Sternberg, C. N., & Studer, U. E. (2012) · European Urology · doi:10.1016/j.eururo.2011.08.026 · Cited by 266
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
Lowrance, W. T., Breau, R. H., Chou, R., Chapin, B. F., Crispino, T., Dreicer, R., Jarrard, D. F., Kibel, A. S., Morgan, T. M., Morgans, A. K., et al. (2021) · Journal of Urology · doi:10.1097/ju.0000000000001375 · Cited by 265
Drug-induced Osteoporosis: Mechanisms and Clinical Implications
Mazziotti, G., Canalis, E., & Giustina, A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.02.028 · Cited by 262
Efstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., & Smith, M. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3752 · Cited by 261
Self-citationManagement of Complications of Prostate Cancer Treatment
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., & Smith, M. R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0002 · Cited by 196
Self-citationGolds, G., Houdek, D., & Arnason, T. (2017) · International Journal of Endocrinology · doi:10.1155/2017/4602129 · Cited by 150
Management of side effects of androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.004 · Cited by 69
Metadata
- Authors
- Smith, M. R., Lee, W. C., Brandman, J., Wang, Q., Botteman, M., & Pashos, C. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-11-01
- Volume
- 23
- Issue
- 31
- Pages
- 7897-7903
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162514583
- Cited by
- 366
- References
- 33
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.